![Douglas Carr](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Douglas Carr
Direttore Finanziario/CFO presso CENTURY THERAPEUTICS, INC.
Patrimonio netto: 852 541 $ in data 30/06/2024
Profilo
Douglas Carr is currently the Director at Heritage Conservancy.
He also holds the position of Senior Vice President-Finance & Operations at Century Therapeutics, Inc. since 2024 and Vice President-Finance at Novira Therapeutics, Inc. since 2018.
Previously, he worked as the Business Director-Franchise Division at Zocor Ltd., Controller-Pediatric Vaccines Franchise at Merck & Co., Inc., Financial Controller at Omthera Pharmaceuticals, Inc., and Vice President-Finance & Operations at Century Therapeutics, Inc. He obtained his undergraduate degree from Rutgers State University of New Jersey.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
07/06/2024 | 334 330 ( 0.40% ) | 852 542 $ | 30/06/2024 |
Posizioni attive di Douglas Carr
Società | Posizione | Inizio |
---|---|---|
CENTURY THERAPEUTICS, INC. | Direttore Finanziario/CFO | 02/02/2024 |
Novira Therapeutics, Inc. | Corporate Officer/Principal | 01/10/2018 |
Heritage Conservancy | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Douglas Carr
Società | Posizione | Fine |
---|---|---|
Century Therapeutics, Inc. /Old/
![]() Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Direttore Finanziario/CFO | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Zocor Ltd. | Corporate Officer/Principal | - |
Omthera Pharmaceuticals, Inc.
![]() Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Comptroller/Controller/Auditor | - |
Formazione di Douglas Carr
Rutgers State University of New Jersey | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CENTURY THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Omthera Pharmaceuticals, Inc.
![]() Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Zocor Ltd. | |
Century Therapeutics, Inc. /Old/
![]() Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Novira Therapeutics, Inc. | |
Heritage Conservancy |
- Borsa valori
- Insiders
- Douglas Carr